Title: Polycystic Ovary Syndrome in Light of Hormonal Panel Interpretations Literature Review
Authors: Dr Teeba Salwan Kamal Abbood, Dr Rand Salwan Kamal Abbood
DOI: https://dx.doi.org/10.18535/jmscr/v13i08.08
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic disorder defined by a triad of ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology (PCOM).
The "hormonal panel" for PCOS includes ovarian and adrenal androgens, gonadotropins, sex hormone–binding globulin (SHBG), anti–Müllerian hormone (AMH), and tests that rule out other conditions (like TSH, prolactin, and 17-hydroxyprogesterone).
In the last ten years, evidence-based guidelines have improved diagnostic and management pathways and have thought about how to interpret certain analytes, especially AMH.
This review consolidates contemporary evidence regarding the diagnostic, phenotyping, and prognostic functions of the hormonal panel in PCOS, emphasizing the advantages and drawbacks of essential biomarkers and presenting practical testing algorithms derived from the 2023 International Evidence-based PCOS Guideline and recent systematic reviews.
References
- International PCOS Network. Recommendations from the 2023 International Evidence‑based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocri-nol Metab. 2023;108(10):2447–2461.
- Teede HJ, et al. The 2023 International Evidence‑based PCOS Guideline (overview webpage). American Society for Reproductive Medicine; 2023.
- Rotterdam ESHRE/ASRM‑Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long‑term health risks related to PCOS. Fertil Steril. 2004;81(1):19–25.
- Azziz R, et al. Diagnosis of PCOS: The Rotterdam Criteria, their advocacy and limitations. J Clin Endocrinol Metab. 2006;91(3):781–785.
- Chang S, et al. Diagnosis of PCOS: Which Criteria to Use? Curr Treat Options Endocr. 2021;7:1–14.
- Peña AS, et al. Current Guidelines for Diagnosing PCOS. J Clin Med. 2023;12(6):1964. (MDPI review summarizing threshold updates, including AFC ≥25)
- Bizuneh AD, et al. Diagnostic accuracy of androgen measurement in PCOS: a systematic review (to inform 2023 Guideline). Hum Reprod Update. 2024;30
- Abdelazim IA, et al. Elevated and diagnostic androgens of PCOS. Prz Menopauzalny. 2020;19(2):63–69.
- Saadia Z, et al. LH/FSH ratio in PCOS and BMI correlation. Cureus. 2020;12(9):e10445.
- Morshed MS, et al. LH:FSH ratio and hyperandrogenemia in PCOS. J Endocrinol Metab. 2021;11
- van der Ham K, et al. Anti‑Müllerian hormone as a diagnostic biomarker for PCOS: meta‑analysis (2024). Fertil Steril. 2024
- di Clemente N, et al. AMH and PCOS: pathophysiology and clinical implications. Int J Mol Sci. 2022;23(20):12115.
- Gorzko A, et al. AMH levels in PCOS across the lifespan. Int J Environ Res Public Health. 2025;22
- Racine C, et al. Blocking AMH reverses reproductive dysfunction in PCOS (preclinical /early translational). Nat Med. 2025
- Rasquin LI, et al. Polycystic Ovarian Syndrome (StatPearls review, updated 2025). NCBI Bookshelf.
- Zhu L, et al. Insulin resistance in PCOS across tissues: mechanisms and implications. J Ovarian Res. 2022;15
- Joham AE, et al. Diagnostic Challenges in PCOS workup (2025). Clin Endocrinol (Oxf). 2025
- Alhassan S, et al. Diagnostic performance of AMH, LH:FSH, TT, PRL among Sudanese women with PCOS. Cureus. 2023;15(5):e
- SHBG‑insulin relationships among PCOS phenotypes (observational). Biomedicines. 2023;11
- Zhao F, et al. High AMH predicts lower live birth after fresh ET in PCOS IVF. Reprod Biol Endocrinol. 2025;23
- Cannarella R, et al. Ketogenic diets in PCOS: systematic review and meta‑analysis. Nutrients. 2025.